The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation announced they will combine in a first-of-its-kind transaction in cancer philanthropy to launch the Samuel Waxman Institute for Aging & Cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 
In Brief

Curebound announces eight grants totaling $2M to address emerging areas of cancer research

Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account